title: [Impacts of atorvastatin on blood lipids and arterial media thickness in new-onset type 2 diabetes patients].
abstract: OBJECTIVE
  To analyze the impact of atorvastatin on blood lipids and arterial media thickness (IMT) in new-onset type 2 diabetes patients.
  
  
  METHODS
  333 patients, 30-70 years old and diagnosed within one year as type 2 diabetes, were selected from the Chinese Diabetes Complication Prevention Study (CDCPS) to take part in this study. Changes of blood lipids and IMT of carotid, femoral and iliac artery pre and post the administration of atorvastatin were tested and followed for 24 months.
  
  
  RESULTS
  Total cholesterol, triglycerides and low-density lipoprotein decreased significantly (P = 0.000) and maintained at a low level. The carotid artery IMT decreased significantly (P = 0.022) at the end of this study, but the femoral and iliac artery IMT did not show any obvious change. There were no serious adverse events noticed, during the study period.
  
  
  CONCLUSIONS
  Long-term use of atorvastatin seemed to be safe and effective in reducing blood lipids in patients with type 2 diabetes thus could delay the development of atherosclerosis.
authors.affiliation: Department of Endocrinology, Beijing Hospital, Ministry of Health, Beijing 100730, China.
authors.forename: Dongni
authors.initials: D
authors.lastname: Yu
authors.affiliation: Department of Endocrinology, Beijing Hospital, Ministry of Health, Beijing 100730, China. Email: wangyoffice@126.com.
authors.forename: Yao
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Endocrinology, Beijing Hospital, Ministry of Health, Beijing 100730, China.
authors.forename: Jiamin
authors.initials: J
authors.lastname: Chi
authors.affiliation: Department of Endocrinology, Beijing Hospital, Ministry of Health, Beijing 100730, China.
authors.forename: Mingxiao
authors.initials: M
authors.lastname: Sun
authors.affiliation: Department of Endocrinology, Beijing Hospital, Ministry of Health, Beijing 100730, China.
authors.forename: Lixin
authors.initials: L
authors.lastname: Guo
authors.affiliation: Department of Endocrinology, Beijing Hospital, Ministry of Health, Beijing 100730, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Jiang
authors.affiliation: Department of Endocrinology, Beijing Hospital, Ministry of Health, Beijing 100730, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Li
authors.affiliation: Department of Endocrinology, Beijing Hospital, Ministry of Health, Beijing 100730, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Endocrinology, Beijing Hospital, Ministry of Health, Beijing 100730, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Pan
authors.affiliation: Department of Endocrinology, Beijing Hospital, Ministry of Health, Beijing 100730, China.
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Endocrinology, Beijing Hospital, Ministry of Health, Beijing 100730, China.
authors.forename: Tongzhang
authors.initials: T
authors.lastname: Xian
mesh_terms: D000328:Adult; D000368:Aged; D000069059:Atorvastatin; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000627:therapeutic use*; D017540:Tunica Media / Q000473:pathology*
chemical_list: D006538:Heptanoic Acids; D008055:Lipids; D011758:Pyrroles; D000069059:Atorvastatin